{"id":3896,"date":"2017-09-06T07:24:24","date_gmt":"2017-09-06T07:24:24","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/"},"modified":"2017-09-06T07:24:24","modified_gmt":"2017-09-06T07:24:24","slug":"viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/","title":{"rendered":"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning"},"content":{"rendered":"
Nanexa har under innevarande kvartal genomf\u00f6rt en omfattande djurstudie
\nmed syfte att visa p\u00e5 m\u00f6jligheter att anv\u00e4nda PharmaShell\u00ae i en parenteral dep\u00e5beredning.<\/strong><\/div>\n

Nanexa har nu erh\u00e5llit resultat fr\u00e5n en PK-studie* i r\u00e5tta d\u00e4r flera doser av en
l\u00e4kemedelssubstans belagd med PharmaShell\u00ae av olika skaltjocklekar j\u00e4mf\u00f6rts med
substans utan PharmaShell\u00ae. Studien genomf\u00f6rdes p\u00e5 Charles River Laboratories\u00a0
anl\u00e4ggning i Skottland. Den varade i tre veckor vilket \u00e4r betydligt l\u00e4ngre \u00e4n den\u00a0
tidigare studien med PharmaShell\u00ae som varade i sex dagar.<\/p>\n

Resultaten fr\u00e5n m\u00e4tningarna av substansen i blodplasma visade att niv\u00e5erna efter en\u00a0
initialt h\u00f6gre koncentration snabbt klingade av till en konstant niv\u00e5, vilken bibeh\u00f6lls\u00a0
genom hela \u00e5terstoden av studien utan tendens till avklingning. Av det kan vi dra\u00a0
slutsatsen att dep\u00e5funktionen varar l\u00e4ngre \u00e4r de tre veckor vi f\u00f6ljde r\u00e5ttorna i denna\u00a0
studie. Dessutom visade resultaten att plasmaniv\u00e5erna var beroende av b\u00e5de dos\u00a0
och skaltjocklek, vilket ger oss viktiga verktyg f\u00f6r att kunna designa\u00a0
l\u00e4kemedelsdep\u00e5er utifr\u00e5n specifika medicinska behov. Arbetet med n\u00e4sta djurstudie\u00a0
\u00e4r ig\u00e5ng med m\u00e5ls\u00e4ttningen att kunna f\u00f6lja hur l\u00e4nge dep\u00e5erna forts\u00e4tter vara\u00a0
verksamma.<\/p>\n

F\u00f6retagets VD David Westberg kommenterar<\/p>\n

Resultatet som presenteras ovan ser jag som v\u00e4ldigt v\u00e4rdefullt f\u00f6r bolaget. Vid\u00a0
utveckling av en dep\u00e5beredning \u00e4r det en konstant plasmaniv\u00e5 av\u00a0
l\u00e4kemedelssubstansen man efterstr\u00e4var f\u00f6r att uppn\u00e5 optimal behandlingseffekt.\u00a0
Utvecklingsarbetet med PharmaShell\u00ae-plattformen, som skett p\u00e5 f\u00f6retagets\u00a0
laboratorium i Uppsala har nu skapat de m\u00f6jligheter som beh\u00f6vs f\u00f6r att kunna ta\u00a0
tekniken vidare in i utvecklingen av en blivande kommersiell l\u00e4kemedelsprodukt. Det\u00a0
\u00e4r sj\u00e4lvklart mycket gl\u00e4djande och viktigt f\u00f6r utvecklingen av bolaget.<\/p>\n

Dokumentationen av f\u00f6retagets PharmaShell\u00ae-plattform st\u00e4rktes ytterligare av\u00a0
studien d\u00e5 vi i kunde konstatera att PharmaShell\u00ae inte p\u00e5verkade v\u00e4vnaden d\u00e4r\u00a0
dep\u00e5n lagts, n\u00e5got som ocks\u00e5 det \u00e4r en mycket viktig parameter vid framtagning av\u00a0
en kommersiell produkt.<\/p>\n

Sammantaget vill jag framh\u00e5lla att vi har tagit ett stort steg fram\u00e5t i utvecklingen av\u00a0
PharmaShell\u00ae och att vi n\u00e4rmar oss en mycket sp\u00e4nnande fas i f\u00f6retagets utveckling.<\/p>\n

F\u00f6r mer information kontakta:
David Westberg – VD, Nanexa AB (publ)
Telefon: 0709 -42 83 03\u00a0
E-post: david.westberg@nanexa.se
www.nanexa.se<\/p>\n

Denna information \u00e4r s\u00e5dan information som Nanexa AB \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s\u00a0
marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg,\u00a0
f\u00f6r offentligg\u00f6rande den 6 september, 2017.<\/p>\n

Om Nanexa AB (publ)<\/p>\n

Nanexa AB \u00e4r ett nanoteknologiskt drug deliveryf\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen\u00a0
av PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor\u00a0
potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa\u00a0
samarbetsavtal med bland andra AstraZeneca och Karolinska Institutet.<\/p>\n

*En farmakokinetisk studie (PK-studie) \u00e4r en studie av hur en l\u00e4kemedelssubstans p\u00e5verkas vid administrering till\u00a0
en levande organism. I en farmakokinetisk studie f\u00f6ljs vanligtvis l\u00e4kemedelssubstansen genom att ta blodprover\u00a0
fr\u00e5n organismen vid ett flertal tidpunkter f\u00f6r att kunna m\u00e4ta halten av den<\/p>\n

\n

Bifogade filer<\/strong><\/p>\n\n

<\/a><\/p>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa har under innevarande kvartal genomf\u00f6rt en omfattande djurstudie med syfte att visa p\u00e5 m\u00f6jligheter att anv\u00e4nda PharmaShell\u00ae i en parenteral dep\u00e5beredning.<\/p>\n","protected":false},"template":"","class_list":["post-3896","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nViktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa har under innevarande kvartal genomf\u00f6rt en omfattande djurstudie med syfte att visa p\u00e5 m\u00f6jligheter att anv\u00e4nda PharmaShell\u00ae i en parenteral dep\u00e5beredning.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\\\/\",\"name\":\"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2017-09-06T07:24:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/","og_locale":"sv_SE","og_type":"article","og_title":"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning - Nanexa AB","og_description":"Nanexa har under innevarande kvartal genomf\u00f6rt en omfattande djurstudie med syfte att visa p\u00e5 m\u00f6jligheter att anv\u00e4nda PharmaShell\u00ae i en parenteral dep\u00e5beredning.","og_url":"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/","url":"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/","name":"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2017-09-06T07:24:24+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/viktiga-resultat-fran-djurstudie-med-pharmashell-som-parenteral-depaberedning\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Viktiga resultat fr\u00e5n djurstudie med PharmaShell\u00ae som parenteral dep\u00e5beredning"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}